TeamDrive
RUS

Leading pharma manufacturers to expand their stocks before Brexit

06 August 2018

GMP News

Sanofi and Novartis mentioned they deliberate to extend stockpiles of medicines Britain in preparation for potential disruption if the UK crashes out of the European Union and not using a deal.

Roche, the world’s largest maker of most cancer medicines, additionally mentioned it was taking “appropriate action” to overview its stock ranges in an effort to shield provides to sufferers.

Britain’s largest drugmaker, GlaxoSmithKline, mentioned it was taking steps to safe the availability of its medicines and vaccines forward of the UK’s departure from the EU, with out going into particulars.

Supplies of 1000’s of medicines are liable to disruption if Britain leaves the EU and not using a deal, forcing producers to arrange duplicate product testing and licensing preparations to make sure their medicine keep on the market.

Leading drugmakers have lengthy been vocal of their considerations about Brexit and the necessity for the prescribed drugs sector to remain throughout the European regulatory system.

British lawmakers have additionally known as for an settlement that enables the nation to have continued participation within the European medicines regulatory framework, nevertheless it stays unclear how it will play out within the broader EU negotiations.

The European Medicines Agency has warned drugmakers they needed to be ready for a possible hard Brexit in 2019. It has also expressed “serious concerns” over the availability of some 108 medicines that are manufactured exclusively in the UK.

Source


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more